Biotech company Amgen (NASDAQ: AMGN) will be reporting earnings this Tuesday after the bell. Here’s what to look for.

Amgen beat analysts’ revenue expectations by 6.6% last quarter, reporting revenues of $9.56 billion, up 12.4% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ revenue estimates and full-year revenue guidance beating analysts’ expectations.

Is Amgen a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Amgen’s revenue to grow 4.3% year on year to $9.47 billion, slowing from the 10.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.76 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Amgen has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 1.9% on average.

Looking at Amgen’s peers in the biotechnology segment, only Regeneron has reported results so far. It beat analysts’ revenue estimates by 2.7%, delivering year-on-year sales growth of 2.5%.

Investors in the biotechnology segment have had steady hands going into earnings, with share prices flat over the last month. Amgen is up 6.7% during the same time and is heading into earnings with an average analyst price target of $332.70 (compared to the current share price of $341.35).

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.